Goldman Sachs downgraded ALI HEALTH's target price from $5.2 to $4.8 and maintained a Neutral rating due to the anticipated negative impact of increased investments in AI and pharmaceuticals on profitability. Despite a modest year-to-date share price decline of 3%, which is better than the HSTECH's 11% drop, the company is expected to see a slight profit decrease in the second half of 2026 as a result of higher AI investments and increased discounts on original drugs to remain competitive.
